Skip to main content

What the FDA labels say about taking them together

Nalbuphine and oliceridine

Oliceridine's FDA label of December 31, 2025 names nalbuphine in its drug interactions section; the nalbuphine label PlainMeds reads does not name oliceridine. The oliceridine label: “May reduce the analgesic effect of OLINVYK and/or precipitate withdrawal symptoms.”

Check it at the source: the nalbuphine FDA label on DailyMed (effective December 31, 2025, Hospira, Inc.); the oliceridine FDA label on DailyMed (effective December 31, 2025, Trevena, Inc.).

What does the nalbuphine label say about oliceridine?

Nalbuphine's label (effective December 31, 2025) does not name oliceridine in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Nalbuphine Hydrochloride), Hospira, Inc., effective December 31, 2025 (SPL set 6025e8d4-5083-4c3a-58a0-050e7b0b6150), via openFDA; the full label on DailyMed

What does the oliceridine label say about nalbuphine?

Oliceridine label, drug interactions

Clinical Impact: May reduce the analgesic effect of OLINVYK and/or precipitate withdrawal symptoms. Intervention: Avoid concomitant use. Examples: butorphanol, nalbuphine, pentazocine, buprenorphine Muscle Relaxants

Oliceridine label, warnings and precautions

Additionally, avoid the use of mixed agonist/antagonist (e.g, pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving a full opioid agonist analgesic, including OLINVYK.

Source: FDA drug label (OLINVYK), Trevena, Inc., effective December 31, 2025 (SPL set ce167984-8b9d-40b7-84ce-d0f33fff1eaa), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

6Nalbuphine generic labelers
0Oliceridine generic labelers
NalbuphineOliceridine
Labeled forPainPain
Boxed warningYesYes
Pharmacy cost (NADAC)$4.32 per mL 10 mg/mL ampuln/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?